Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer

被引：2
|
作者：
Joris, Sofie [1 ]
Fontaine, Christel [1 ]
Decoster, Lore [1 ]
Vanacker, Leen [1 ]
Schallier, Denis [1 ]
De Greve, Jacques [1 ]
机构：
[1] UZ Brussel, Oncol Ctr, Dept Med Oncol, Jette, Belgium
来源：
BREAST JOURNAL | 2019年 / 25卷 / 04期
关键词：
chemotherapy; breast cancer; elderly; FEBRILE NEUTROPENIA; DOCETAXEL/CYCLOPHOSPHAMIDE;
D O I：
10.1111/tbj.13306
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) is adopted worldwide as a valuable option for elderly patients with high-risk early breast cancer. Some studies suggest that paclitaxel may have a better therapeutic ratio than docetaxel. Therefore we have implemented an adjuvant chemotherapy in which docetaxel was replaced by paclitaxel. We report here the retrospective analysis of that cohort and make a safety comparison with an earlier TC cohort in the same target population. This retrospective analysis demonstrates the feasibility of paclitaxel/cyclophosphamide as an alternative, better tolerated adjuvant regimen for elderly patients. Further evaluation and assessment of noninferiority to TC is warranted.
引用
收藏
页码：663 / 666
页数：4
相关论文
共 50 条
  • [21] Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients
    Coltelli, Luigi
    Fontana, Andrea
    Lucchesi, Sara
    Ginocchi, Laura
    Bocci, Guido
    Filidei, Mario
    Scalese, Marco
    Arrighi, Giada
    Finale, Chiara
    Marcucci, Lorenzo
    Goletti, Orlando
    Salvadori, Barbara
    Ferrarini, Ilaria
    Bona, Eleonora
    Falcone, Alfredo
    Allegrini, Giacomo
    BREAST, 2017, 31 : 186 - 191
  • [22] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Midori Morita
    Akihiko Shimomura
    Emi Tokuda
    Yoshiya Horimoto
    Yukino Kawamura
    Yumiko Ishizuka
    Katsutoshi Sekine
    Sayaka Obayashi
    Yuki Kojima
    Yukari Uemura
    Toru Higuchi
    Breast Cancer, 2022, 29 : 498 - 506
  • [23] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Morita, Midori
    Shimomura, Akihiko
    Tokuda, Emi
    Horimoto, Yoshiya
    Kawamura, Yukino
    Ishizuka, Yumiko
    Sekine, Katsutoshi
    Obayashi, Sayaka
    Kojima, Yuki
    Uemura, Yukari
    Higuchi, Toru
    BREAST CANCER, 2022, 29 (03) : 498 - 506
  • [24] Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer
    Denise A. Yardley
    Lowell Hart
    David Waterhouse
    Robert Whorf
    D. Randolph Drosick
    Patrick Murphy
    Suprith Badarinath
    Brooke R. Daniel
    Barrett H. Childs
    Howard Burris
    Breast Cancer Research and Treatment, 2013, 142 : 655 - 665
  • [25] Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer
    Yimeng Chen
    Baoshi Bao
    Yao Lv
    Decong Sun
    Li Zhang
    Jiandong Wang
    Weihong Zhao
    Investigational New Drugs, 2021, 39 : 524 - 529
  • [26] Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Kelly Brogan
    Katherine S. Panageas
    Carol Pearce
    Larry Norton
    Ann Jakubowski
    Marjorie Zauderer
    Jane Howard
    Clifford Hudis
    Breast Cancer Research and Treatment, 2005, 92 : 151 - 156
  • [27] Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Hurria, A
    Brogan, K
    Panageas, KS
    Pearce, C
    Norton, L
    Jakubowski, A
    Zauderer, M
    Howard, J
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 92 (02) : 151 - 156
  • [28] The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
    Campbell, H. E.
    Epstein, D.
    Bloomfield, D.
    Griffin, S.
    Manca, A.
    Yarnold, J.
    Bliss, J.
    Johnson, L.
    Earl, H.
    Poole, C.
    Hiller, L.
    Dunn, J.
    Hopwood, P.
    Barrett-Lee, P.
    Ellis, P.
    Cameron, D.
    Harris, A. L.
    Gray, A. M.
    Sculpher, M. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) : 2517 - 2530
  • [29] Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
    Schwartz, J
    Domchek, SM
    Hwang, WT
    Fox, K
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 247 - 252
  • [30] Refractory breast cancer: A comparison of two different chemotherapy regimens
    Erkisi, M
    Bilkay, BC
    Seyrek, E
    Hazar, B
    Burgut, R
    JOURNAL OF CHEMOTHERAPY, 1997, 9 (06) : 442 - 445
12345